Sapanisertib

在生命科学与医药研发的竞技场上，时间就是论文，效率就是竞争力。然而，搭建一个斑马鱼实验平台绝非易事——从养殖系统的建设维护、基因编辑模型的构建，到高通量筛选平台的技术攻关，不仅需要大量的前期资金投入，更依赖于一支经验丰富的专业技术团队。正因如此，越来越多的科研机构、高校实验室和医药企业选择将斑马鱼实验外包给专业CRO服务机构，以最快的速度、最低的成本获取最可靠的实验数据。本文将从行业趋势、外包优势、避坑要点等维度，全面解析斑马鱼实验外包这一“科研快车道”。一、斑马鱼：从“水中小白鼠”到科研新宠斑马鱼之所以能在短短十余年间从实验室的“后来者”跃升为药物研发和生命科学研究的主流模式生物，其背后有着坚实的科学基础。斑马鱼与人类基因同源性高达87%，胚胎体外发育且全身透明，在显微镜下可直接观察多种组织器官的动态变化。成年雌鱼单次产卵超过200枚，72小时即可从胚胎发育成幼鱼，繁殖快、周期短、通量高，这些特性使其成为唯一可用于高通量筛选的脊椎动物模型。近年来，斑马鱼在疾病模型构建领域成果斐然：复旦大学生命科学学院罗凌飞团队成功构建了早衰斑马鱼模型，并从中筛选出具有延缓衰老潜力的抗癌药物sapanisertib；棕榈酸诱导的斑马鱼代谢相关脂肪性肝病模型能够跨物种复现小鼠和人类的关键疾病通路，为代谢疾病研究提供了全新工具；斑马鱼抑郁症模型的建模方法也在不断完善，相关研究正处于快速发展阶段。疾病模型覆盖了从肿瘤、心血管、神经退行性疾病到代谢性疾病、炎症免疫异常等几乎所有重点研究领域。二、市场规模持续扩大，外包成为主流趋势斑马鱼技术应用的快速拓展直接推动了斑马鱼服务市场的蓬勃发展。据QYResearch最新数据，2025年中国斑马鱼服务市场规模已达数亿元人民币，预计到2032年将增长至352百万美元，2026—2032年间年复合增长率高达15.4%。从全球范围来看，斑马鱼服务市场同样保持强劲增长势头，预计从2026年的1.59亿美元增长至2032年的3.57亿美元。行业数据显示，2023年国内斑马鱼实验市场规模约8.7亿元，年增速超过16%。然而，具备SPF资质的专业机构不足50家，规模化企业偏少，长三角地区独占产能60%以上。市场正呈现出头部企业向“斑马鱼+类器官+小鼠”一体化服务发展，中小企业以基础实验为主的格局。随着基因编辑技术的普及、AI成像和自动化筛选平台的涌现，斑马鱼技术服务正朝着标准化、智能化和合规化的方向快速演进。三、为什么要选择斑马鱼实验外包？1. 大幅降低时间成本自建一个合规的斑马鱼实验平台，从场地规划、设备采购到人员培训、体系搭建，通常需要一年以上的周期。而选择外包服务，从方案确认到数据交付往往仅需数周。在当今“快鱼吃慢鱼”的科研竞赛中，这种时间优势往往意味着论文发表的先发制人和项目申报的优先权。2. 节省资金投入，性价比突出斑马鱼实验的综合成本仅为小鼠实验的1/10至1/100，实验周期通常仅需1至5天，性价比极为突出。通过外包，课题组无需投入数十万甚至上百万资金用于养殖系统、显微成像设备等硬件购置，也免去了水质监控、鱼房运维等持续性的运营开支。更重要的是，外包服务商提供的实验数据可直接用于课题研究，避免了因设备或技术不足导致的实验失败和重复投入。3. 获取专业团队的技术保障斑马鱼实验涉及养殖繁育、基因编辑、显微注射、行为分析、病理检测、分子生物学等多学科交叉技术，对从业人员的综合素质要求较高。当前行业普遍面临“懂鱼、懂分子、懂表型分析”的复合型人才稀缺困境。而专业的CRO服务机构通常拥有多年深耕斑马鱼领域的核心技术团队，能够确保实验设计的科学性、操作的规范性和数据的可复现性。4. 获得合规背书与标准化数据在药物注册申报、保健食品备案、化妆品功效宣称等场景中，实验数据需要满足GLP或AAALAC等认证要求。专业外包机构具备合规的实验动物使用许可和标准化的质量管理体系，其出具的数据报告在监管采信方面更具权威性，这对于新药IND申报、产品功效备案等具有直接的商业价值。四、选择外包服务，如何避开那些“坑”？斑马鱼实验外包虽然优势显著，但市场上机构良莠不齐，选择不当反而可能“花钱买教训”。以下是几个避坑要点：看资质：优先选择具备实验动物使用许可证、通过GLP或AAALAC认证的机构，这是数据合规性的基础保障。查质控：水质参数、鱼龄批次、菌群环境的一致性直接影响实验结果的可复现性。建议实地考察或在合作前索取质控体系说明。比团队：核心团队是否具有斑马鱼领域的专业背景和长期从业经验？技术负责人是否在相关学术领域有积累？团队实力是服务质量的根本保障。验案例：是否有与自身研究方向相近的成功案例？能否提供可供参考的项目经验？案例验证是最直接的筛选方式。审方案：实验方案是否科学、透明、可溯源？数据交付是否包含原始影像和统计分析的完整链路？五、百环生物：斑马鱼实验外包的专业之选在众多斑马鱼技术服务提供商中，百环生物凭借其深厚的技术积淀和完善的服务体系脱颖而出，成为越来越多科研机构和医药企业的合作首选。深耕斑马鱼领域，技术底蕴扎实百环生物是一家聚焦大健康领域、以科研创新为核心驱动力的综合性生物技术服务企业。公司核心成员拥有15年以上的斑马鱼实验经验，在斑马鱼模型构建、药效评价、毒理安全测试等方面积累了丰富的技术底蕴。2025年11月，百环生物总经理刘永利、首席技术官朱晓宇博士应邀参加多家三甲医院举办的医工交叉创新交流会，围绕斑马鱼技术在药效评价及临床科研中的应用进行了深度分享，展示了公司在医药研究领域的独特价值和创新成果。多维技术平台，构建“多位一体”服务体系百环生物立足打造“科学循证测评 + 食品功能评价 + 药理药效研究 + 精选原料”全生命周期服务科技平台，协同AI分子本草、线虫、无菌动物（蜜蜂+小鼠）、斑马鱼、哺乳动物、人体试食等多元化技术，构建“多位一体”的综合性技术服务体系，提供AI智能配方开发、功效研究、机制研究、科学循证、注册申报、科技营销、安全评价等全方位技术服务。依托斑马鱼模型、基因编辑、无菌模型、类器官及纳米医学等前沿技术，百环生物形成了覆盖模型构建、药效评价、机制研究的全生命周期服务体系。自主研发实验设备，打通技术全链条作为斑马鱼实验室整体解决方案的领导者，百环生物不仅提供技术服务，更打造了包含斑马鱼实验设备、AI分析模型、技术输出、试剂耗材、基因工程品系在内的多位一体服务方案。公司拥有自主研发的斑马鱼专用成像系统、行为分析仪、血流分析仪、耐力测试系统、自动化养殖系统等先进设备，并专门针对斑马鱼特性研发了酶活/因子专用试剂盒，解决了市面上通用试剂盒在斑马鱼实验中“水土不服”的痛点。此外，公司还可提供从实验室规划设计到设备安装调试、技术培训的全套智慧实验室建设服务。四大实验基地，近50人专业团队在硬件与团队实力上，百环生物已在北京、广州、杭州、南京完成四大实验基地与运营中心布局，实验室总面积超过4000平方米，严格遵循合规标准。技术团队规模近50人，其中博士、硕士以上学历16人，高级职称2人，组建了涵盖哺乳动物、斑马鱼、线虫等领域的综合性专家技术团队。公司采用CRISPR/Cas9等精准基因编辑技术，能够定制数百种疾病模型，覆盖肿瘤、心血管、神经退行性疾病、代谢性疾病等多个研究领域。科学循证赋能，打通“从实验室到市场”最后一公里百环生物创新性地提出“科学循证”理念，不仅为科研客户提供实验技术服务，更为大健康产品企业提供从功效验证、注册申报到科技营销的一站式解决方案。公司为优质产品颁发科学循证证书、制作科学传播视频、提供专利申报和学术文章支撑服务，将产品的技术语言转化为市场语言，真正当好“功效翻译官”，实现科研成果与商业价值的双重突破。在斑马鱼实验领域，技术门槛、时间成本和资金投入是横亘在科研人员面前的三座大山。选择一家专业、可靠、经验丰富的斑马鱼技术服务伙伴，不仅能让课题研究事半功倍，更能为成果转化铺平道路。百环生物以15年+的行业深耕、多位一体的技术平台、自主的设备研发能力和专业的科学循证服务，正帮助越来越多的科研机构、医院和企业跨越技术鸿沟，加速科研成果从实验室走向临床应用和市场的进程。让专业的人做专业的事，把宝贵的科研精力留给更有价值的创新探索——这或许就是斑马鱼实验外包最朴素也最有力的理由。返回搜狐，查看更多

BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. “The first quarter of 2026 was transformational for the Company, with the acquisition of Faeth Therapeutics and the concurrent $200 million private placement in February, supported by a group of leading life sciences investors,” said Christopher Gerry, President & General Counsel of Sensei Biotherapeutics. “This acquisition and injection of new capital will allow us to advance PIKTOR, a differentiated multi-node pathway inhibitor, through key clinical milestones.” “New data across the industry continues to support the significant potential of multi-node inhibition of the PI3K/AKT/mTOR pathway,” said Anand Parikh, Chief Operating Officer of Sensei Biotherapeutics. “We believe PIKTOR is differentiated as an orally administered multi-node therapy specifically targeting PI3K-alpha, mTORC1 and mTORC2, with the potential to treat a variety of solid tumors. With our Phase 2 trial in advanced endometrial cancer expected to read out by the end of the year and the recent initiation of our Phase 1b/2 trial in advanced breast cancer, we are making great strides towards delivering the next generation of solid tumor therapies.” Clinical Program Highlights Acquired through the Faeth transaction, PIKTOR is now Sensei’s lead program. The investigational, proprietary, all-oral combination of serabelisib and sapanisertib is designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting. In April 2026, the first patient was dosed in the Phase 1b/2 trial evaluating PIKTOR for the treatment of HR+/HER2- advanced breast cancer (Study FTH-PIK-101). Interim data from the trial is expected in 2027. The Phase 2 trial evaluating PIKTOR in advanced endometrial cancer (Study FTH-PIK-201) is on track to report topline data in the second half of 2026. First Quarter 2026 Financial Results Cash Position: Cash, cash equivalents and marketable securities were $202.8 million as of March 31, 2026, as compared to $21.2 million as of December 31, 2025. Research and Development (R&D) Expenses: R&D expenses were $18.0 million for the quarter ended March 31, 2026, compared with $3.7 million for the quarter ended March 31, 2025. The increase in R&D expenses was primarily attributable to the inclusion of Faeth R&D operations as well as one-time costs associated with the Faeth acquisition, partially offset by a reduction in the SNS-101 clinical trial costs. General and Administrative (G&A) Expenses: G&A expenses were $19.7 million for the quarter ended March 31, 2026, compared to $3.5 million for the quarter ended March 31, 2025. The increase in G&A expense was primarily attributable to one-time costs associated with the Faeth acquisition. Acquired In-Process Research and Development (Acquired IPR&D) Expenses: Acquired IPR&D expenses were $133.0 million for the quarter ended March 31, 2026. This represents the fair value of IPR&D assets obtained in connection with asset acquisition where the acquired IPR&D has no alternative future use as of the acquisition date. Net Loss: Net loss was $170.2 million, or $131.45 per basic and diluted share, for the quarter ended March 31, 2026, compared with a net loss of $6.9 million, or $5.45 per basic and diluted share, for the quarter ended March 31, 2025. Weighted-average common shares outstanding, basic and diluted, were 1,295,052 for the quarter ended March 31, 2026, compared with 1,259,531 for the quarter ended March 31, 2025. Condensed Statements of Operations (Unaudited, in thousands except share and per share data) For the Three Months Ended March 31, 2026 2025 Operating expenses: Research and development $ 17,957 $ 3,725 General and administrative 19,713 3,549 Acquired in-process research and development 132,957 — Total operating expenses 170,627 7,274 Loss from operations (170,627 ) (7,274 ) Total other income 391 410 Net loss (170,236 ) (6,864 ) Net loss per share, basic and diluted $ (131.45 ) $ (5.45 ) Weighted-average common shares outstanding, basic and diluted 1,295,052 1,259,531 Selected Condensed Balance Sheet Data (Unaudited, in thousands) March 31, 2026 December 31, 2025 Cash and cash equivalents $ 152,325 $ 8,668 Marketable securities 50,468 12,516 Total assets 205,381 22,902 Total liabilities 14,191 4,310 Series B redeemable convertible preferred stock 328,476 — Total stockholders’ (deficit) equity (137,286 ) 18,592 About Sensei Biotherapeutics Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. Following the acquisition of Faeth Therapeutics, Sensei's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. Sensei is also completing a Phase 1/2 trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Sensei intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, please visit www.senseibio.com and follow the company on X @SenseiBio and LinkedIn. Cautionary Note Regarding Forward-Looking Statements Certain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to the company’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the expected benefits or opportunities following the acquisition of Faeth Therapeutics; expectations regarding or plans for the company’s pipeline, including the Phase 2 trial evaluating PIKTOR in advanced endometrial cancer and the expected timing for topline data, the Phase 1b/2 trial evaluating PIKTOR in HR+/HER2- advanced breast cancer and the expected timing for interim data, the completion of the remaining portion of the Phase 1/2 trial of solnerstotug and other research and development programs and the expected timing for key milestones; the potential benefits of PIKTOR, including its potential to treat a variety of solid tumors; expectations regarding the use of proceeds from the private placement and cash runway expectations therefrom, including such proceeds funding the company through key clinical milestones. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "opportunity," "potential," "milestones," "pipeline," "can," "goal," "aim," "strategy," "target," "seek," "anticipate," "achieve," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "predict," "project," "should," "will," "would" and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the company will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those uncertainties and factors described under the heading "Risk Factors" and "Summary of Risk Factors" in the company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on May 14, 2026, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by the company from time to time, as well as risk factors associated with companies, such as Faeth, that operate in the biotechnology industry. Should one or more of these risks or uncertainties materialize, or should any of the company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The company does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in the company.